The United Kingdom's National Health Service sees med tech as crucial to addressing healthcare improvements. It's launched a series of 7 trials with several major technology partners designed to test several means of integrating med tech specifically into at-home care for elderly and chronic disease patients.
The U.K.'s Competition and Markets Authority (CMA) is planning to levy "substantial fines" this year, marking a "big step up in the scale and impact" of its enforcement activity, Alex Chisholm, head of the agency, told The Financial Times. And one of those fines will likely be directed at a pharma company, Chisholm said, as the CMA probes drugmakers including GlaxoSmithKline and Pfizer for alleged wrongdoing.
The United Kingdom has committed a further $375 million to its massive sequencing initiative, the 100,000 Genomes Project. Government officials are making the extra cash available to finance the introduction of whole-genome sequencing into the National Health Service.
AstraZeneca has unveiled a clutch of deals to add to the technological capabilities of its new R&D hub in Cambridge, U.K. The agreements will equip the site with robots to carry out high-throughput screening, sound wave tools to dispense compounds and software to share data with external partners.
Last fall, Acacia Pharma's virtual crew cheered the late-stage success of a drug designed to prevent postoperative nausea and vomiting by bringing in strategic advisers to help hammer out a path forward. And evidently, they concluded that setting out to raise $230 million on the London Stock Exchange was the right way to go.
The U.K.'s special cancer drugs fund gave the heave-ho to a slate of treatments, including Roche's cutting-edge breast cancer treatment Kadcyla and Celgene's Abraxane for pancreatic cancer. Drugmakers are hopping mad, cancer treatment charities are despairing--and the fund and some public officials are on the defensive.
Novartis won't have to wait for European regulators to do a full-force data sift before its new heart failure drug becomes available in England. The U.K. will allow Novartis to roll out its Entresto drug under an early-access scheme begun last year.
UCL has made Elsevier's PharmaPendium available to its researchers. The United Kingdom academic institution has subscribed to the resource to support its staffers' research into drug repurposing and the personalization of treatments.
The United Kingdom has opened up another front of its 100,000 Genomes Project. Having started off sequencing the genomes of people with rare diseases, the team behind the initiative are now ready to take aim at their other big target: cancer.
The movement to shift informed consent in clinical trials from paper forms to electronic devices has notched up another victory. Mytrus and an unnamed top-10 pharma company made the advance by becoming the first organizations to win clearance to use e-consent in a trial in the United Kingdom.